{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:37:03Z","timestamp":1791387423502,"version":"4.3.3"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T00:00:00Z","timestamp":1677974400000},"content-version":"am","delay-in-days":338,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100010186","name":"Brooke Army Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010186","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010463","name":"U.S. Army Medical Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010463","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009898","name":"Defense Health Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009898","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ijantimicag.2022.106560","type":"journal-article","created":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T10:56:00Z","timestamp":1646477760000},"page":"106560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Comparing outcomes among outpatients treated for pyelonephritis with oral cephalosporins versus first-line agents"],"prefix":"10.1016","volume":"59","author":[{"given":"Peter E.","family":"Fosse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Brinkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah M.","family":"Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline E.","family":"Conner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James K.","family":"Aden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8863-6879","authenticated-orcid":false,"given":"Stephanie E.","family":"Giancola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2022.106560_bib0001","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2022.106560_bib0002","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1086\/319370","article-title":"Mechanisms of action of antimicrobials: focus on fluoroquinolones","volume":"32","author":"Hooper","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106560_bib0003","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/archinte.163.4.402","article-title":"Trimethoprim\u2013sulfamethoxazole revisited","volume":"163","author":"Masters","year":"2003","journal-title":"Arch Intern Med"},{"issue":"Suppl 2","key":"10.1016\/j.ijantimicag.2022.106560_bib0004","first-page":"S27","article-title":"Pharmacokinetics and pharmacodynamics of fluoroquinolones","volume":"4","author":"Drusano","year":"1998","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2022.106560_bib0005","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jama.283.12.1583","article-title":"Comparison of ciprofloxacin (7 days) and trimethoprim\u2013sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial","volume":"283","author":"Talan","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2022.106560_bib0006","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/520427","article-title":"Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA)","volume":"29","author":"Warren","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106560_bib0007","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/003655401750173922","article-title":"Fewer bacterial relapses after oral treatment with norfloxacin than with ceftibuten in acute pyelonephritis initially treated with intravenous cefuroxime","volume":"33","author":"Cronberg","year":"2001","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106560_bib0008","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1007\/s10096-018-3371-y","article-title":"A systematic review of randomised clinical trials for oral antibiotic treatment of acute pyelonephritis","volume":"37","author":"Cattrall","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106560_bib0009","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1128\/AAC.06060-11","article-title":"In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010","volume":"56","author":"Sanchez","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106560_bib0010","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1128\/AAC.02897-15","article-title":"Antibiotic resistance among urinary isolates from female outpatients in the United States in 2003 and 2012","volume":"60","author":"Sanchez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106560_bib0011","series-title":"FDA drug safety communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects","year":"2016"},{"key":"10.1016\/j.ijantimicag.2022.106560_bib0012","series-title":"FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes","year":"2018"},{"key":"10.1016\/j.ijantimicag.2022.106560_bib0013","series-title":"FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients","year":"2018"},{"key":"10.1016\/j.ijantimicag.2022.106560_bib0014","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1503\/cmaj.111152","article-title":"Considerations when prescribing trimethoprim\u2013sulfamethoxazole","volume":"183","author":"Ho","year":"2011","journal-title":"CMAJ"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2022.106560_bib0015","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1093\/clind\/15.Supplement_1.S216","article-title":"Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration","volume":"15","author":"Rubin","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106560_bib0016","series-title":"Military Health System Management Analysis and Reporting Tool (M2) fact sheet","year":"2019"},{"key":"10.1016\/j.ijantimicag.2022.106560_bib0017","series-title":"Pharmacy Data Transaction Service (PDTS) interface control document describing the data exchange to the MDR","year":"2011"},{"key":"10.1016\/j.ijantimicag.2022.106560_bib0018","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2215\/CJN.01290308","article-title":"Epidemiology of acute infections among patients with chronic kidney disease","volume":"3","author":"Dalrymple","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ijantimicag.2022.106560_bib0019","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2007.09.002","article-title":"A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400\/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis","volume":"71","author":"Peterson","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.ijantimicag.2022.106560_bib0020","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0140-6736(12)60608-4","article-title":"Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial","volume":"380","author":"Sandberg","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2022.106560_bib0021","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/emj.19.1.19","article-title":"Short-term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women. A randomised controlled trial","volume":"19","author":"Sanchez","year":"2002","journal-title":"Emerg Med J"},{"key":"10.1016\/j.ijantimicag.2022.106560_bib0022","doi-asserted-by":"crossref","first-page":"86S","DOI":"10.1016\/0002-9343(92)90614-H","article-title":"Loracarbef (LY163892) versus cefaclor and norfloxacin in the treatment of uncomplicated pyelonephritis","volume":"92","author":"Hyslop","year":"1992","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2022.106560_bib0023","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/cid\/cir838","article-title":"Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia","volume":"54","author":"Pulcini","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106560_bib0024","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/ACI.0000000000000755","article-title":"Classifying cephalosporins: from generation to cross-reactivity","volume":"21","author":"Fernandez","year":"2021","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"Suppl 3","key":"10.1016\/j.ijantimicag.2022.106560_bib0025","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1469-0691.2000.tb02049.x","article-title":"Oral cephalosporins in uncomplicated urinary tract infections","volume":"6","author":"Garc\u00eda-Rodr\u00edguez","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2022.106560_bib0026","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1093\/cid\/ciu574","article-title":"Making sense of cephalosporin and amoxicillin\/clavulanate susceptibility testing for uropathogens","volume":"59","author":"Nguyen","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106560_bib0027","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.ajem.2018.08.016","article-title":"Pyelonephritis treatment in the community emergency department: cephalosporins vs. first-line agents","volume":"36","author":"Vogler","year":"2018","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.ijantimicag.2022.106560_bib0028","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane\u2013tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2022.106560_bib0029","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2174\/1871526515666150831144801","article-title":"Empirical treatment in patients with acute obstructive pyelonephritis","volume":"15","author":"Pasiechnikov","year":"2015","journal-title":"Infect Disord Drug Targets"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922000541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922000541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:36:31Z","timestamp":1767137791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857922000541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0924857922000541"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106560","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing outcomes among outpatients treated for pyelonephritis with oral cephalosporins versus first-line agents","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106560","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106560"}}